Print this article

Carl-Åke Carlsson – CEO of Xellia Pharmaceuticals

Click HERE to download the PDF version

 

What was the plan when Xellia first emerged in 2008?
We were the market leader for almost all of our anti-infectives, supplying more than half the world market. Our aim was simply to take the APIs (Active Pharmaceutical Ingredients), develop them into formulations, have them registered and get them onto the market. At the same time, we developed a generic pipeline of new anti-infective injectables. In 2012, 3i decided to sell rather than invest in another five to seven-year period. We were lucky to find Novo Holdings A/S, which now owns us through the same investment vehicle that owns Novo Nordisk, Novozymes